NCT00068783View on ClinicalTrials.gov

S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

June 30, 2007

Conditions
Recurrent Neuroendocrine Carcinoma of the SkinStage II Neuroendocrine Carcinoma of the SkinStage III Neuroendocrine Carcinoma of the Skin
Interventions
DRUG

imatinib mesylate

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

78245

Southwest Oncology Group, San Antonio

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00068783 - S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer | Biotech Hunter | Biotech Hunter